Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells  by Wei, Heming et al.
FEBS Letters 579 (2005) 1272–1278 FEBS 29273Statin-inhibited endothelial permeability could be associated with its
eﬀect on PECAM-1 in endothelial cells
Heming Weia,b,1, Lu Fanga,1, Jie Songa, Subroto Chatterjeea,b,c,*
a Laboratory of Atherosclerosis and Vascular Biology, Johns Hopkins Singapore-National Heart Centre Vascular Biology Program,
31 Biopolis Way, #03-00 The Nanos Building, Singapore 138669, Singapore
b Department of Pediatrics, Lipid Research Unit, Suite 312, 550 North Broadway, Johns Hopkins University, Baltimore, MD 21205, USA
c Department of Biochemistry, National University of Singapore, Singapore
Received 13 October 2004; revised 3 January 2005; accepted 4 January 2005
Available online 26 January 2005
Edited by Beat ImhofAbstract The 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors (statins) are known to inhibit leukocyte recruit-
ment to endothelium but the mechanism is less understood.
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is an
endothelial junction protein involved in leukocyte diapedesis.
We hypothesize that in endothelial cells, statins may well recruit
PECAM-1 to exert their inhibitory eﬀect on leukocyte trans-
endothelial migration (TEM). In lovastatin-treated resting hu-
man umbilical vein endothelial cells (HUVECs), increased levels
of mRNA and protein of PECAM-1 as well as its bio-synthesis
(all 2-fold) were observed by real-time PCR, Western blotting
and 35S-labeled methionine incorporation assay, respectively.
Moreover, in lovastatin treated resting cells as well as TNF-a
activated endothelial cells, unanimously decreased Triton X-
100 insoluble and soluble PECAM-1 ratio was observed. Such
changes were accompanied by decreased TEM of U-937 cells
(a promonocyte cell line). All lovastatins eﬀects were abrogated
by mevalonic acid. In resting HUVECs, geranylgeranyl pyro-
phosphate (GGPP), but not farnesyl pyrophosphate (FPP) (both
are isoprenoid intermediates in the cholesterol biosynthesis path-
way) compromised the eﬀect of lovastatin on PECAM-1 expres-
sion, whereas C3 toxin, an inhibitor of small G proteins, exerted
statin-like eﬀect.
Conclusion: Statin-reduced endothelial permeability could be
attributed to altered intracellular distribution of PECAM-1 in
endothelial cells. We speculate that lovastatin regulates PE-
CAM-1 expression in HUVECs through the mevalonate-GGPP
pathway by inhibiting of Rho small GTPase.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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A group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (statins) has been commonly used
for the treatment of hypercholesterolemia via the inhibition
of cholesterol synthesis in the liver by blocking the conversion*Corresponding author. Fax: +1 410 614 2826.
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doi:10.1016/j.febslet.2005.01.020of HMG-CoA to mevalonate [1]. In recent years, the pleiotro-
pic eﬀects of statins, including a wide variety of vascular eﬀects
such as inhibiting vascular inﬂammation, have been recognized
[2–5]. The eﬀects of statins, for example, upregulation of eNOS
expression, have been attributed to the inhibition of Rho pro-
tein [6,7]. Nevertheless, knowledge about the detailed biochem-
ical basis of statins pleiotropic eﬀects is still limited.
Vascular inﬂammation has been associated with atherogene-
sis which has been hypothesized as an inﬂammatory process
characterized by enhancing the recruitment of leukocyte to-
wards dysfunctional endothelium [8,9]. This process is predom-
inantly mediated by a group of cellular adhesion molecules
(CAMs) expressed on the cell surface, such as selectins, intercel-
lular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1) and platelet endothelial cell adhesion
molecule-1 (PECAM-1, CD 31). PECAM-1 is one of the endo-
thelial junction proteins playing a distinct role in leukocyte
trans-endothelial migration (TEM) as it has been demonstrated
in both in vivo [10–12] and in vitro [13,14] studies.
Although various reports have shown that statins can reduce
cell adhesion and transmigration [2,4,15], so far studies uncov-
ering the endothelial responses to statin treatment at the
molecular level have been limited to the expression of cell
adhesion molecules such as VCAM-1, ICAM-1 and E-selectin,
etc. [16,17], which are involved in leukocytes tethering and
adhesion to endothelium, the mechanism of statins inhibitory
eﬀect on TEM at the molecular level, however, has yet to be
explored.
We speculate that statins inhibitory eﬀect on leukocyte
TEM could well recruit PECAM-1 in endothelial cells. It
may also involve Rho geranylgeranylation. In this study, com-
prehensive eﬀects of statin(s) on altering the expression and
intracellular distributions of PECAM-1 in both resting and
TNF-a activated human endothelial cells have been uncovered
and further linked to the inhibition of Rho small GTPase. To-
gether, our data suggest that statins inhibition of leukocytes
TEM involves the altered cellular distribution of PECAM-1
via inhibition of Rho A GTPase.2. Materials and methods
2.1. Cell culture
Primary HUVECs and endothelial culture media (EGMe) were
purchased from Cloneticse, Biowhitttaker, East Rutherford, NJ. HU-
VECs were cultured on gelatin (0.2%)-coated surface in EGMe sup-ation of European Biochemical Societies.
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ium (RPMI 1640) was purchased from Invitrogen, Carlsbad, CA. U-
937 cell line, a human pro-monocyte cell line (CRL-1593.2), was pur-
chased from American Type Culture Collection (ATCC), Bethesda,
MD and cultured in RPMI 1640 medium supplemented with 10%
FBS. Fresh human peripheral mononuclear cells (MNC) were isolated
from the venous blood of healthy volunteers with Ficoll-Hypaquee
(Amersham–Pharmacia Biotech AB, Uppsala, Sweden) following the
manufacturers protocol.
HUVECs of passage 3–4 were pre-incubated with various reagents
in EGMe supplemented with 2% FBS. Following incubations, cell via-
bility was tested by trypan blue exclusion method. Further, apoptotic
eﬀect was tested by 4 0,6 0-diamidino-2-phenylindole hydrochloride
(DAPI) staining and a cytoplasmic histone-associated DNA fragmen-
tation assay with a Cell Death Detection ELISA kit from Roche, Ger-
many. No marked cytotoxicity or apoptosis were observed in our
study. HUVECs were subjected to series of experiments including PE-
CAM-1 gene/protein expression assays and monocyte TEM assays
simultaneously. Each experiment was repeated for at least three times
with diﬀerent batches of primary HUVECs.2.2. Reagents and antibodies
Lovastatin (M2147), mevalonic acid (M4667), GGPP (G6025), and
FPP (F6892) were purchased from Sigma–Aldrich Corporation, St.
Louis, MO. Simvastatin (MK-733) was purchased from Calbiochem,
San Diego, CA. Clostridium botulinum C3 transferase (C3 toxin)
was purchased from List Biological Laboratories Inc., Campbell,
CA. Anti-PECAM-1 monoclonal antibody (mAb) (1 mg/mL, clone
9G11, Cat. #BBA7) from R&D Systems, Minneapolis, MN, was used
for immunoblotting and immunoﬂuorescence assay at 1:500 and 1:250
dilutions, respectively. [35S]methionine was purchased from Amer-
sham, UK. A rabbit polyclonal antibody (IgG), named ‘‘JHS-7’’,
which we synthesed for our previous study [18], was raised against a
30 amino acids synthetic peptide homology to the 5th extracellular
(Ig)-like domain of PECAM-1 and showed high speciﬁcity by recogniz-
ing both denatured and native PECAM-1. JHS-7 was used in the
immunoprecipitation and TEM assay.2.3. Gene transcription assay
Total RNA was isolated from HUVECs with Trizol Reagent
(Invitrogen) following the manufacturers instructions. After DNase
I (RNase free, Roche) treatment, ﬁrst-strand complementary DNA
(cDNA) was synthesized by reverse transcription (RT) primed with
both an oligo d(T)15 and a random hexamer using a standard protocol.
Real-time polymerase chain reactions (real-time PCR) were prepared
using SYBR GREEN PCR MASTER MIX (Cat. #4309155) from
Applied Biosystems, Warrington, UK. The PCRs were carried out
on iCyclerTM IQ (real-time PCR machine from Bio-Rad). The se-
quences of PCR primers (listed as forward primers (5 0–3 0) and reverse
primers (5 0–3 0) followed by the sizes of PCR products (number of base
pairs)) are: PECAM-1: gctgacccttctgctctgtt and tgagaggtggtgctgacatc
(150); and b-actin: CATGTACGTTGCTATCCAGGC and
CTCCTTAATGTCACGCACGAT (250). b-actin gene served as an
internal control. PCRs were performed by repeating the following
ampliﬁcation cycle 32 times: denaturing at 94 C for 45 s followed by
annealing at 60 C for 45 s and extension at 72 C for 60 s. Results
from the real-time PCR were presented as threshold cycles normalized
to that of b-actin gene according to the method of Overbergh et al.
[19]. It reversibly represented the concentration (number of copies)
of cDNA template of individual gene.2.4. Western blot assay
HUVECs were washed with PBS and lyzed by M-PERe mammalian
protein extraction reagent (Pierce Biotechnology Inc., Rockford, IL)
with the addition of 10% Completee EDTA-free Protease Inhibitor
Cocktail (Roche). Equal amounts (25 lg) of total protein from total
HUVEC lysate or Triton X-100 (TX-100) soluble/insoluble fractions
were subjected to 10% sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and Western immunoblotting assay probed
by primary monoclonal antibodies (mAb) followed by secondary rab-
bit IgG and ﬁnally visualized by enhanced chemiluminescence. All
blots were stripped and re-probed with anti-b-actin antibody. Protein
quantiﬁcations were performed with densitometry scanning of theWestern blot images of both PECAM-1 and b-actin. All of the PE-
CAM-1 quantiﬁcations (shown as bar graphs) were conducted by stan-
dardization against b-actin.2.5. PECAM-1 biosynthesis in HUVECs
HUVECs were incubated with diﬀerent concentrations of lovastatin
for 5 and 15 h. Next, the medium was replaced with labeling medium
(methionine free medium supplemented with 35S-labeled methionine
(100 lCi/mL) supplemented with lovastatin of same concentration
above mentioned). Incubation was continued for an additional hour.
Next, the HUVECs lysate was prepared and subjected to immunopre-
cipitation according to a standard procedure [20] with an anti-PE-
CAM-1 antibody (JHS-7). Finally, samples were loaded onto a 10%
SDS–PAGE gel, resolved by electrophoresis, and autoradiographic
images were obtained subsequently.2.6. Preparation of detergent-soluble and insoluble (cytoskeleton)
fractions
Triton X-100 soluble and insoluble fractions were prepared from cell
lysate (2 · 106 HUVECs) according to Amos et al. [21]. The purity of
detergent soluble/insoluble fractions was veriﬁed by detecting the pres-
ence of intercellular cell adhesion molecule-1 (ICAM-1) using Western
blot assay (data not shown) as ICAM-1 is known predominantly pre-
sents in the soluble fraction only [21].2.7. Immunoﬂuorescent confocal microscopy
HUVECs were grown on 8-well plastic chamber slides (Lab-Tek
Chamber Slide Nalge Nunc Int. Corp., IL) and subjected to the same
treatments as for the Western blot assay. Then cells were ﬁxed in 4%
formaldehyde in PBS for 30 min at room temperature and subse-
quently permeabilized in 0.2% TX-100 in PBS for 15 min on ice. Then
the cells were incubated with primary anti-PECAM-1 mAb (1:250) for
1 h followed by secondary FITC-conjugated anti-rabbit IgG (1:300)-
for 1 h at room temperature. The ﬂuorescent images were viewed using
confocal microscopy.2.8. Transmigration assay
Leukocyte TEM assays were performed on a Transwell design (A
plate of 12 wells equipped with insert upper wells with 3-lm pore size
polycarbonate membrane bottom from Costar, Cambridge, MA.)
according to a protocol described previously [22]. In brief, HUVECs
(105 cells) were seeded on gelatin (0.2%)-coated upper wells and al-
lowed to grow for 2 days until conﬂuence. Conﬂuent HUVEC mono-
layers were pre-incubated with lovastatin at diﬀerent doses for 16 h.
Next, 106 U-937 cells were added in each upper well containing fresh
medium without (lovastatin) and allowed to transmigrate through
the HUVEC monolayers for 12 h at 37 C with 5% CO2. Finally,
U-937 cells migrated to the bottom wells were collected and counted.
TEM was determined as a percentage of the control. Analysis was car-
ried out in quadruplicates. Freshly isolated human MNCs were used to
verify the results with U-937 cells.2.9. Statistics
Data are presented as means ± standard deviation (S.D.). All statis-
tical tests were calculated from three or more independent experiments.
Comparisons were made by paired t test, and a P value less than 0.05
was considered statistically signiﬁcant.3. Results
3.1. Lovastatin stimulates PECAM-1 expression and
bio-synthesis in resting HUVECs
Lovastatin (2.5 and 5 lM) stimulated the expression of the
mRNA (Fig. 1A) and the PECAM-1 protein in HUVECs
(Fig. 1B). To examine whether the observation above was a
class eﬀect, HUVECs were incubated with simvastatin (0.5
and 1.0 lM), which also stimulated PECAM-1 protein expres-
sion (data not shown). Metabolic labeling studies using
Fig. 1. Statins stimulate PECAM-1 gene/protein expression and
biosynthesis in resting HUVECs. Conﬂuent HUVECs were incubated
with lovastatin or simvastatin, plus mevalonic acid for 16 h. (A)
HUVEC RNA was isolated and gene transcription level of PECAM-1
was determined by real-time PCR. (a) Representative PCR images and
(b) data plotted as threshold cycles normalized to b-actin gene and it
reversibly represents the concentration (copies) of cDNA template of
PECAM-1 gene. (B) HUVECs were treated by both lovastatin and
simvastatin and cell lysate was prepared and PECAM-1 protein was
determined by for SDS–PAGE and Western blotting assay. (a)
Representative Western blot image and (b) bar graph of protein
quantiﬁcation plotted from not less than three independent experi-
ments. (C) Autoradiographic image of 35S-labeled methionine PE-
CAM-1 immunoprecipitated (by anti-PECAM-1 antibody, JHS-7)
from lysate of HUVECs treated with lovastatin. (a) Representative
electrophoric graph and (b) bar graph plotted from two independent
experiments were presented. *P < 0.05; **P < 0.01; ***P < 0.001.
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novo PECAM-1 biosynthesis in HUVECs (Fig. 1C). Since
statins inhibit the activity of hydroxymethyl-glutaryl coen-
zyme-A reductase and consequently block the conversion of
HMG-CoA to mevalonate, we simultaneously investigated
the eﬀect of mevalonic acid on PECAM-1 expression. Asshown in Fig. 1, mevalonic acid at 200 lM almost completely
reversed lovastatin induced PECAM-1 gene/protein expression
and biosynthesis in HUVECs. Signiﬁcant eﬀects of statins on
PECAM-1 gene/protein expression were observed with 16 h
incubation while shorter incubation times failed to increase
PECAM-1 levels signiﬁcantly (data not shown). Thus, we
adopted a ﬁxed 16-h incubation time and using lovastatin pri-
marily in all of our subsequent experiments.3.2. Lovastatin altered the intracellular distributions of
PECAM-1 in HUVECs
To determine the potential eﬀect of lovastatin on the sub-
cellular localization of newly synthesized PECAM-1 in HU-
VECs, cell lysate was separated into detergent-soluble and
insoluble fractions with TX-100 and PECAM-1 protein
was quantiﬁed employing Western blot assay. In lova-
statin-treated HUVECs, more PECAM-1 was detected in
the detergent-soluble fraction (4.5-fold increase) than that
of control while no change was observed in the detergent-
insoluble fractions, and the eﬀect of lovastatin was reversed
by mevalonic acid (Fig. 2A(a)). The localizations of PE-
CAM-1 in resting HUVECs were further determined
employing immunoﬂuorescent staining and confocal micros-
copy. PECAM-1 was found predominantly localized in the
cytosolic side adjacent to cell membrane and lovastatin
(5.0 lM) treatment led to a dramatic increase in PECAM-
1 immunostaining in the cytosolic/sub-membrane area. Mev-
alonic acid subsequently reversed the impact of lovastatin
(Fig. 2A(b)).
In contrast to lovastatins eﬀect, TNF-a alone decreased
total PECAM-1, mainly in the detergent-soluble fraction, in
HUVECs after 4 h pre-activation (Fig. 2B). Subsequent treat-
ment of the TNF-a pre-activated HUVECs with lovastatin
(5.0 lM) failed to restore the level of total PECAM-1 (Fig.
2B), but dramatically reversed the altered distributions of PE-
CAM-1 in detergent soluble/insoluble fractions: the level of
detergent-soluble PECAM-1, which was signiﬁcantly reduced
by TNF-a, was greatly restored, in contrast, PECAM-1 in
detergent-insoluble fraction was decreased (Fig. 2B). Addi-
tional treatment with mevalonic acid compromised the eﬀect
of lovastatin (Fig. 2B). The ratio of detergent-soluble versus
insoluble PECAM-1 is around 4:1 in resting HUVECs and
2:1 in TNF-a activated HUVECs.3.3. Lovastatin decreases the TEM of U-937 cells
Decrease of the U-937 Cell TEM through the monolayers of
lovastatin (1.25, 2.5 and 5.0 lM) (Fig. 3A) or simvastatin (0.5
and 1.0 lM) (data not shown) treated HUVECs was observed
and this was reversed by mevalonic acid. TNF-a alone mark-
edly increased the TEM of U-937 cells and it was partially
abrogated by lovastatin, and mevalonic acid compromised
the eﬀect of lovastatin (Fig. 3B). Results from the TEM assay
using U-937 cells were veriﬁed with human mononuclear cells
(data not shown).
3.4. Lovastatin activated PECAM-1 expression and reduced
endothelial permeability in resting HUVECs following the
mevalonate-GGPP pathway via inhibiting small G proteins
By inhibiting L-mevalonate synthesis, statins also prevent
the synthesis of other important isoprenoid intermediate in
Fig. 2. Intracellular distributions of PECAM-1 in lovastatin-treated HUVECs. HUVECs incubated with lovastatin (5.0 lM) for 16 h were subjected
to detergent extraction and PECAM-1 was quantiﬁed by Western blot assays. (A) Eﬀect of lovastatin on resting HUVECs. (a) Representative
Western blot image showing detergent-soluble (TX-100) and insoluble PECAM-1 and bar graph of protein quantiﬁcation plotted from no less than
three independent experiments. (b) Immunoﬂuorescent staining of PECAM-1 in HUVEC of control, lovastatin (5.0 lM), and lovastatin plus
mevalonic acid (200 lM). Cells were ﬁxed with 4% formaldehyde and further permeabilized with 0.2% TX-100. White arrows indicate the
immunoﬂuorescent staining of PECAM-1 at HUVEC cell–cell junctions. (B) Eﬀect of lovastatin on TNF-a treated HUVECs. TNF-a treated
HUVECs were incubated with lovastatin, plus mevalonic acid for 16 h. Cell lysate was separated into detergent-soluble/insoluble fractions and
PECAM-1 protein was determined by for Western blotting assay. 25 lg protein per lane was loaded. Representative Western blot image and bar
graph of protein quantiﬁcation of detergent soluble/insoluble PECAM-1 plotted from no less than three independent experiments were presented.
*P < 0.05; **P < 0.01; ***P < 0.001.
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In order to determine which downstream isoprenoid interme-
diate regulates PECAM-1 expression, HUVECs were treated
with lovastatin in the presence of isoprenoid intermediate,
GGPP or FPP.GGPP (10–20 lM), but not FPP at the same
concentrations (FPP at 20 lM not shown), were able to reverse
lovastatins eﬀect on PECAM-1 protein expression (Fig. 4A).
To determine whether the inhibition of Rho mediates the ef-
fects of lovastatin on PECAM-1 expression, HUVECs were
treated with C3 toxin, an inhibitor of small G proteins, and in-
creased PECAM-1 protein expression was found and this eﬀect
was not compromised by mevalonic acid (Fig. 4A). Decrease
of the U-937 Cell TEM through the monolayers of C3 toxin
(50 ng/mL) treated HUVECs was also observed (Fig. 4B).
Moreover, a PECAM-1 antibody, JHS-7, but not control
IgG, compromised the eﬀect of lovastatin on TEM (Fig. 4B).
Collectively, these studies suggest that lovastatin induces PE-
CAM-1 expression in HUVECs through the mevalonate-
GGPP pathway by inhibiting small G proteins.4. Discussion
Accumulating evidence has indicated that hypolipidemic
drug statins possess pleiotropic eﬀects, such as restoring endo-
thelial function and decreasing vascular inﬂammation beyondtheir lipid lowering action [2–4,23–26]. Statins are known to
attenuate the recruitment of circulating leukocytes to endothe-
lium including leukocytes rolling, adhesion, and transmigra-
tion [2,4,5,15,27], which represents a hallmark of vascular
inﬂammation. Previous studies are limited to the impact of
statins on ICAM-1, VCAM-1, E-selectin and P-selectin
[2,16,17,27,28] which are inducible endothelial CAMs with
functional relevance conﬁned to leukocyte tethering and adhe-
sion [29].
Our current results, for the ﬁrst time, unveiled the molecular
response of PECAM-1 to statin treatment in endothelial cells,
a change at the molecular level, which could help to explain the
mechanism of attenuated monocytes TEM. Statin unani-
mously altered the intracellular distribution of PECAM-1 in
a way that favors less formation of cytoskeleton stress ﬁbers
in both resting and TNF-a activated endothelial cells. More-
over, statin-inhibited Rho GTPase is found to regulate the
expression of PECAM-1. Taking together, we speculate that
in statin-treated HUVECs, the change of PECAM-1 expres-
sion and distributions, regulated via inhibiting RhoA GTPase,
contributes to the inhibition of TEM. The eﬀect of lovastatin
could be a class eﬀect of statins because similar eﬀects on PE-
CAM-1 expression and U-937 cell TEM have been achieved by
simvastatin.
First, PECAM-1/Cytoskeletal Interactions could directly
regulate monocyte TEM. PECAM-1 is possibly able to bind
Fig. 4. Lovastatin induced increase in PECAM-1 expression through
the mevalonate-GGPP pathway by inhibiting small G proteins.
Conﬂuent HUVECs were incubated with lovastatin and co-treated
with mevalonic acid, GGPP, FPP, or treated alone with C3 toxin for
16 h and cell lysates was prepared and subjected to 10% SDS–PAGE
with mAbs against PECAM-1. A(a) Representative Western blot
image and (b) bar graph of protein quantiﬁcation plotted from not less
than three independent experiments. (B) Eﬀects of an anti-PECAM-1
antibody (JHS-7), a control antibody (rabbit IgG), and C3 toxin along/
or co-incuabted with lovastatin for 16 h on TEM. Bar graphs were
calculated from no less than three independent experiments each in
quadruplicates. *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 3. Lovastatin decreases the transendothelial migration of pro-
monocyte (U-937 cells). Conﬂuent HUVECs monolayers pre-incu-
bated with lovastatin, plus mevalonic acid for 16 h were subjected to
monocyte TEM assays. (A) Lovastatin and simvastatin dose-depen-
dently inhibited U-937 cell TEM through resting HUVEC monolayers.
(B) Lovastatin abrogates TNF-a increased U-937 Cells TEM through
the monolayers of HUVEC conﬂuent pre-activated with TNF-a. Bar
graphs were calculated from no less than three independent experi-
ments each in quadruplicates. *P < 0.05; **P < 0.01; ***P < 0.001.
1276 H. Wei et al. / FEBS Letters 579 (2005) 1272–1278to and coordinate the assembly of F-actin ﬁlaments. A func-
tional relationship between PECAM-1 and the cytoskeleton
is being recognized as growing evidence has showed that PE-
CAM-1 associates both physically and functionally with the
underlying cytoskeleton [30,31]. It has been reported that the
reorganization of actin cytoskeleton (stress ﬁber formation),
and redistribution of a group of endothelial cell tight junc-
tion proteins from the TX-100-soluble to the TX-100-insolu-
ble fractions are associated with transendothelial
permeability in brain endothelial cells [32]. Triton-insoluble
cytoskeleton is largely composed of F-actin ﬁlament and PE-
CAM-1 is associated with both the Triton insoluble and sol-
uble cytoskeleton and its distribution depends on the
activation state of the cell [33]. For example, during throm-
bin-induced platelet aggregation, PECAM-1 partitions with
the Triton-insoluble cytoskeleton increased from 10% to
60% of total cellular PECAM-1 [33]. In conﬂuent endothelial
cells, 20% to 30% of PECAM-1 was found associated with
the cytoskeleton [31,34] and it increased to 65% during cell
migration [31].
During TEM, endothelial cells will undergo morphological
changes perhaps re-organization of its intracellular F-actin ﬁl-
aments to facilitate the passing of leukocytes. In this study, in
resting HUVECs, TX-100 insoluble PECAM-1 made 30% of
total PECAM-1 and it increased to 70–80% in TNF-a acti-
vated HUVECs, while subsequent lovastatin treatment de-
creased the ratio of TX-100 insoluble PECAM-1 to 10–15%
in resting HUVECs and to 30% in TNF-a pre-activated HU-
VECs, respectively. Decreased portion of TX-100 insoluble
PECAM-1, in this case, could lead to decreased formation of
F-actin, ﬁlament stress ﬁber and reduce the permeability of
endothelium.In addition, it is also known that mAb-induced cross-linking
of PECAM-1 on the cell surface of NK cell could induce cell
spreading and cytoskeletal rearrangement [35]. A combination
of VE-cadherin-speciﬁc and PECAM-1-speciﬁc antibodies re-
sulted in reorganization of F-actin ﬁlaments into discrete foci
[36]. Since it is well known that anti-PECAM-1 antibodies
attenuate leukocytes TEM, thus JHS-7 Ab in our study serves
as a control. JHS-7, but not control IgG, comprised the eﬀect
of lovastatin on TEM (Fig. 4B), which suggest the involvement
of PECAM-1 in the TEM of U-937 cells.
Next, PECAM-1 could be an important Rho GTPase-regu-
lated molecule involved in statins endothelial protective ac-
tions. Statins lipid lowering [37] and pleiotropic eﬀects have
been associated with the inhibition of Rho family small G pro-
teins of [38–40]. Indeed, statins induced activation of eNOS
follows this pathway [7,37]. It has been found that Rho
GTPase regulates the actin cytoskeleton [32,41] and control
polarity, protrusion, and adhesion during cell movement [42].
Changes in the intracellular distributions of endothelial junc-
tion molecules and the formation of actin cytoskeleton and
TEM have been associated with Rho and Rho kinase [32].
Interestingly, PECAM-1 has been found to modulate endothe-
lial cell motility through the small G-protein Rho [43]. Our
data conﬁrmed that indeed lovastatin activated the gene/pro-
tein expressions of PECAM-1 following mevalonate-GGPP
pathway via inhibiting RhoA small GTPase, similar to the
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CAM-1 expression and U-937 cell TEM were compromised
by GGPP and mimicked by C3 Toxin, which inhibits RhoA
GTPase activity [7].
In TNF-a and statin treated HUVECs, the expression pat-
tern of PECAM-1 is quite similar to eNOS [7]. We found that
the total cellular PECAM-1 was upregulated by statins, but
downregulated by TNF-a which is in sharp contrast to
VCAM-1, ICAM-1 and E-selectin (data not shown). VCAM-
1, ICAM-1 and E-selectin are inducible in endothelial cells
by pro-inﬂammatory cytokines such as TNF-alpha via activa-
tion of NF-jB activity [44–46]. Our ﬁnding support that PE-
CAM-1 is a diﬀerent CAM as compared with VCAM-1,
ICAM-1 and E-selectin [47] and the precise role of PECAM-
1 is still under investigation.
In summary, our study suggests that in statin-treated endo-
thelial cells, the change of PECAM-1 expression and distribu-
tions, regulated via inhibiting RhoA GTPase, could contribute
to reduced endothelial permeability and leukocyte TEM.
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